Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab 40 mg in Relapsed/Refractory Hodgkin Lymphoma
NCT03343665Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by First Saint Petersburg State Medical University. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03343665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343665.